neurosurgical focus
Spinal cord stimulation (SCS) is one of the surgical procedures that has the potential to improve suffering among patients with PPNP. Through controlled delivery of electrical impulses to the dorsal columns of the spinal cord, the putative mechanisms are thought to include both orthodromic and antidromic activation of A-b fibers, recruitment of supraspinal nuclei to augment descending inhibitory impulses, and altered CSF neurochemistry. 16, 17, 23, 26 Patients are commonly exposed to trial stimulation using an external neurostimulator that activates either percutaneously or surgically implanted leads, after which they are implanted with an implantable pulse generator if appropriate analgesia is achieved. Figure 1 presents an illustrative example of a patient implanted with such a device. With appropriately selected patients at centers with interdisciplinary expertise, the trial-to-implant conversion rates can be quite encouraging: in the 65%-80% range for various diagnoses, 15 although from a nationwide perspective, the actual conversion rate remains less encouraging at approximately 41%. 7 The utility of this technology has been demonstrated in prospective randomized and observational studies, and in systematic literature reviews for various pathologies, including PPNP after structurally corrective lumbar spinal surgery, 6 complex regional pain syndrome, 27 chronic inoperable limb ischemia, 31 treatment-refractory angina, 28 and painful diabetic neuropathy. 3 Despite its proven efficacy for the PPNP population, there have been a few small studies that reported on the risk experienced by patients undergoing such intervention specifically in the context of managing neuropathic pain after lumbar spinal surgery, and whether those rates of complication are variable by surgical technique. While percutaneous placement of single-column electrode leads may be less invasive, surgical placement of multicolumn paddles may enhance outcome and protect against device migration.
21, 33 The goal of this narrative review is to examine the evidence supporting safety of the SCS technique among patients being managed for PPNP after lumbar spinal surgery for degenerative disease.
methods electronic literature search
We conducted a systematic search in MEDLINE for literature published through December 2014, limiting the search results to human studies published in the English language. Reference lists of key articles were also systematically checked to identify additional eligible articles. The key question focused on the complications of SCS procedures specifically for the management of neuropathic pain after structurally corrective spinal surgery. Terms for this condition have variably included failed-back surgery syndrome, postlaminectomy pain syndrome, and PPNP. The study population was over the age of 18 years and we included only prospective studies of randomized controlled trial (RCT) or observational cohort design. Case reports or case series that consisted of fewer than 10 patients were excluded. Other studies excluded were animal, cadaveric, and biomechanical studies, and those that did not report complications. Table 1 summarizes this selection process.
data extraction and Analysis
We extracted the following data from the included articles: study design, patient demographics, surgical technique (percutaneous vs open implantation), and perioperative and follow-up complications. Summary statistics regarding overall reported complication rates were generated by pooled estimates based on study size. These are reported as related to implants, therapeutic efficacy, and biological types. Variability in complications between implants placed surgically and percutaneously was assessed at the 0.05 level of significance.
results study selection
The search strategy identified 752 articles, of which 586 represented discrete patient cohorts. Forty-eight were selected for full-text review, from which 37 were fur- ther excluded on the basis of reporting only about trials, performing retrospective analysis, no reporting of complications, or SCS therapy was not specifically used for the management of neuropathic pain after lumbar spinal surgery. Consequently, 11 articles were found suitable for reporting complications, of which 2 were arms of randomized controlled trials 11,19 and 9 represented prospective observational studies. Table 2 summarizes the studies included for analysis of perioperative and long-term complications found on follow-up. Of the 11 studies, there was a total of 542 patients with implanted SCS devices who were followed up for a study median of 24 months and a patient mean of 19 months. The overall duration of follow-up was longer for the RCTs (patient mean 29 months vs 18 months; p < 0.05). Among 8 studies that reported the technique by which the SCS leads were introduced (4 surgically and 4 percutaneously), the overall duration of follow-up was longer for the surgically introduced systems (patient mean 21 months vs 14 months; p < 0.05).
In the 542 patients followed in this work, there were 184 complications. Of these, 74 were related to the SCS device itself, 69 were related to the therapy, and 41 represented biological complications. Table 3 summarizes complications related to the SCS device. The most common among these included lead migration or misplacement (12.2%; range 5%-21%) with no significant difference among systems that were implanted surgically (14%) versus percutaneously (12%). Other device-related complications included implantable pulse generator failure (0.4%), migration (0.2%), and wire breakage (1.5%).
Therapy-related complications are summarized in Table 4. Loss of therapeutic efficacy was observed in 4% of cases (range 0%-14%), although this was only described among patients with devices placed percutaneously. Pain at the sites of device implantation occurred in 9% of cases, and this was more frequent among those devices placed surgically (12%) than those placed percutaneously (7%; p < 0.05). Table 5 summarizes the biological complications associated with SCS therapy. Wound complications of infection and dehiscence were observed in 5% of patients (range 0%-14%). Such problems were noted more frequently among devices that were placed surgically (5%) than those placed percutaneously (2%; p < 0.05).
discussion
Low-back pain remains one of the dominant complaints for which patients seek medical attention. Surgical intervention can provide for improvements in pain and disability, and expedite return to work in appropriately selected patients; however, there remains a significant fraction of patients who exhibit PPNP and for whom conservative management strategies fail to provide relief. This condition can cause substantial pain and disability. In RCTs, neuromodulation in the form of SCS has demonstrated effectiveness in controlling the pain and reducing narcotic use in patients with persistent neuropathic pain following structurally corrective spinal surgery.
12, 19 This can be done cost effectively with the cost offset by postimplant health care use and return to work, 9,18,29 although the same benefit has not been reproducible in the workers' compensation setting. 30 As the number of index spine surgical procedures continues to grow to address increasing need among both active and aging populations, there is a need to better understand the safety profile of these procedures that are used to intervene when the index decompression or fusion procedure does not alleviate suffering.
The 2 RCTs examining this technology for PPNP compared the use of SCS technology either with conventional medical management (CMM) or further structural reoperation. Kumar and coworkers 12 compared SCS and CMM and found that substantial pain relief was observed among 58% and 17% of patients, respectively, with prominent improvements noted for leg pain and no durable differences observed for back pain. North compared SCS with structural reoperation and found substantial pain relief among 47% versus 11% of patients, respectively, with stability or decreased narcotic use noted in 87% of SCS patients and increased narcotic use noted in 42% of reoperation patients. There is recent evidence that implementation of this technology is more efficacious when done sooner after the patient develops neuropathic pain, with the propensity of different subspecialties to initiate referral for SCS being a significant contributor to variability in wait times. 10 Cost-effectiveness studies have been performed on the cited Kumar et al.
12 and North et al. 19 RCTs. When compared with CMM, the incremental cost-effectiveness ratio was $5149 per quality-adjusted life year, implying that it is a highly cost-effective intervention for restoring meaningful quality of life.
9 When compared with spinal reoperation, SCS was the dominant intervention; it was both less expensive and more effective in PPNP patients. 18 Levy and coworkers 13 performed a nationwide study on neurological complications after using surgical paddles for SCS across all indications; the study involved about 44,857 patients. The rare complication for a spinal epidural hematoma (EDH) was observed in 0.19% of patients, two-thirds of whom exhibited substantial motor deficit. Further, sensory and motor deficits without EDH were observed in 0.1% and 0.13%, respectively, suggesting either contusive injury or substantial space occupancy by the leads. While rare, these complications are not benign, and they certainly warrant discussion with patients upon deciding to implement this therapy for the management of disabling neuropathic pain.
Complication avoidance is important to consider in what is essentially an invasive surgical procedure for the management of treatment-refractory pain. Application of minimally invasive spine surgical techniques decreases the approach-related morbidity, limiting bone removal during the laminotomy, operative duration, and associated blood loss. 4, 25 Local wound application of antimicrobial therapy at the surgical site may decrease infection rates for those leads implanted by more extensive laminectomy, although prospective randomized trials exploring this are lacking.
2 While neurological complications remain rare, their avoidance is paramount because of the high rate of morbidity associated with contusive or compressive spinal cord injury. Preoperative assessment with MRI around the implant region is essential to ensure an adequate spinal canal cross-sectional area to accommodate the additional volume of the device. Bleeding risk for EDH occurrence remains even several days following surgery, and decisions about medications affecting coagulation should be carefully considered, particularly if their indication is primary prevention.
Techniques decreasing surgical invasiveness offer only advantage and should be implemented if they are within the armamentarium of the implanting surgeon. Neurophysiological monitoring is particularly important for implants placed under general anesthesia, to monitor for cord injury by altered somatosensory evoked potentials. Such a change should prompt the surgeon to either abort or alter the surgical plan. Common techniques to protect against electrode migration include anchoring devices to secure wires to ligamentous structures or fascia, and the use of strain-relief loops in the subcutaneous compartment to protect against device movement within the canal.
limitations
This is a narrative review of prospective studies, 2 randomized and 9 observational. The rigor of data collection regarding complications is difficult to assure; however, this was done in all studies with high rates of follow-up and in a prospective fashion. Among these 11 studies, 6 were industry funded, 4 reported no funding source, and 1 was funded by national-and state-level peer-reviewed funding. Certainly there is potential for reporting bias, although this study reviewed prospectively collected complication data and not efficacy of the therapy, and may be less impacted by such support mechanisms. The use of SCS devices to control PPNP can provide for improvement in pain and reduction in medication use among patients who failed to achieve benefit with structural spinal surgery for degenerative lumbar disease. Prospective studies formed the basis of this review and reveal a high rate of minor complications of which both patients and clinicians should be aware. Many of these require further surgical intervention to manage, including lead migration or implant infection, although the complication itself does not threaten patient life or function. The incidence of transient or permanent neurological deficit from spinal cord dysfunction is extremely rare but may require emergent neurosurgical intervention or carry substantial disability. Based on largely high-quality, prospective evidence, we find that SCS can be performed safely to manage the care of patients with PPNP. 
